Method for relieving SCA3 and brain lesions through electromagnetic contact continuous transcranial permeation

Abstract

The invention discloses a method for relieving SCA3 and brain lesions through electromagnetic contact continuous transcranial permeation. The method comprises the following steps: S1, constructing a treatment system based on a direct digital synthesis (DDS) technology; s2, performing multi-part electrode layout and treatment parameter setting; and S3, implementing continuous electromagnetic waveform penetration treatment. The invention relates to the technical field of medical rehabilitation, in particular to a method for relieving SCA3 and cerebral lesions through electromagnetic contact continuous transcranial permeation, which has the following advantages: 1, the nerve activation and metabolism efficiency is enhanced; 2, the system has a systematic motion and language repairing function; 3, non-invasive safety intervention and precise adaptation are carried out; and 4, the limitation of the existing therapy is broken through.

Description

Technical Field

[0001] The present invention relates to the field of medical rehabilitation technology, and in particular to a method for alleviating SCA3 and brain lesions through continuous transcranial penetration through electromagnetic contact. Background Art

[0002] Spinocerebellar ataxia type 3 (SCA3) is a neurodegenerative disease caused by CAG trinucleotide repeat expansion in the ATXN3 gene, characterized by apoptosis of neurons in the cerebellum, brainstem, and spinal cord, leading to symptoms such as movement disorders and language disorders. Current treatments for SCA3 and brain lesions have significant limitations:

[0003] 1. Transcranial magnetic stimulation (TMS): uses intermittent pulse stimulation, which only briefly activates neurons and lacks the continuous current to promote metabolism, resulting in insufficient nutritional support for nerve cells;

[0004] 2. Direct current stimulation (DCS): It relies on a constant current, has no waveform changes, and cannot form magnetic field oscillations to accelerate metabolite excretion and nerve repair;

[0005] 3. Gene therapy and drug therapy: Gene therapy is still in the preclinical stage, and drugs can only relieve superficial symptoms such as spasms, and have no substantial improvement on core functional disorders such as movement and language.

[0006] The core problem of existing technologies is the lack of means to continuously and systematically activate diseased brain tissue and the nervous system, and the inability to effectively solve key problems such as the accumulation of mutant protein toxicity, inefficient neural metabolism, and dysfunction of multiple parts of the body. Summary of the Invention

[0007] In light of this, the present invention aims to provide a method for alleviating SCA3 and other brain lesions through continuous transcranial electromagnetic infiltration. This method uses a specific waveform current to simultaneously stimulate multiple sites in the cerebellum, vestibule, spinal cord, and peripheral nerves, creating a continuous potential difference and dynamic magnetic field oscillations to accelerate the metabolism of diseased tissues and activate neural repair pathways. This method transcends the limitations of traditional techniques for single-site stimulation and provides a systematic solution for the rehabilitation treatment of SCA3 and other brain lesions.

[0008] The technical solution of the embodiment of the present invention is achieved as follows:

[0009] The method of electromagnetic contact continuous transcranial penetration to alleviate SCA3 and brain lesions includes the following steps:

[0010] S1. Build a treatment system based on direct digital synthesis (DDS) technology;

[0011] S2. Perform multi-site electrode layout and treatment parameter settings;

[0012] S3. Implement continuous electromagnetic waveform infiltration treatment;

[0013] Wherein: S1, constructing a treatment system based on direct digital synthesis technology (DDS) includes configuring the hardware and software of a DDS bioelectric therapy instrument, wherein the hardware includes a waveform generator, a power amplifier, and body surface electrodes, and the software includes adjustable waveform parameters;

[0014] S2, performing multi-site electrode layout and treatment parameter setting to place electrodes at corresponding surface locations of the bilateral cerebellum, vestibular area, spinal cord, and peripheral nerves, and setting waveform parameters according to the patient's MRI and genetic test results;

[0015] The S3, implementation of continuous electromagnetic waveform penetration therapy is based on a configured treatment system and set parameters, and continuous electromagnetic energy is transmitted to the target tissue through electrodes to promote the metabolism of the diseased tissue and activate the function of nerve cells.

[0016] Preferably, when constructing the treatment system in S1, the waveform generator adopts a direct digital synthesis module, and the body surface electrodes include scalp electrodes, spinal cord electrodes and limb electrodes.

[0017] Preferably, the waveform parameters adjustable by the software in S1 include a frequency range of 1-100 Hz, an amplitude range of 0.1-2 mA, and a duty cycle range of 50%-80%.

[0018] Preferably, the multi-site electrode layout in S2 includes placing ring electrodes on the bilateral cerebellum and vestibular area (on both sides of the occipital protuberance), and placing sheet electrodes on the corresponding surface positions of the cervical vertebrae (C2-C7), thoracic segments (T4-T10), and lumbar segments (L1-L5) of the spinal cord, as well as on the brachial plexus (supraclavicular fossa) and sciatic nerve (subgluteal area).

[0019] Preferably, the treatment parameter settings in S2 include setting the initial frequency to 20-30 Hz, gradually increasing to 50-80 Hz, each treatment time is 30-50 minutes, once a day, 10 times as a course of treatment, and the next course of treatment is carried out after an interval of 3-5 days.

[0020] Preferably, when continuous electromagnetic waveform penetration therapy is implemented in S3, the electrode patch is coated with conductive gel and fixed to the target area so that the impedance is less than 5kΩ; after the instrument is started, the waveform is gradually increased from low intensity to the patient's tolerance threshold.

[0021] Preferably, the multi-site electrode layout in S2 includes determining the surface projection positions of the cerebellum and spinal cord lesion areas through MRI images, placing ring electrodes at the corresponding scalp positions of the bilateral cerebellum and vestibular areas, placing sheet electrodes at a specific distance away from the cervical, thoracic and lumbar spinal cords, and placing circular electrodes at the surface projection points of the brachial plexus and sciatic nerve. The electrode type and position are adjusted according to the patient's lesion site.

[0022] Preferably, the treatment parameter setting in S2 includes determining the initial waveform frequency, amplitude and duty cycle in combination with the patient's genetic test results and disease stage, gradually adjusting the intensity according to the patient's physical feedback during treatment, and the single treatment time and treatment interval are determined according to the severity of the disease.

[0023] Preferably, when continuous electromagnetic waveform penetration therapy is implemented in S3, the electrode patch needs to be coated with a conductive medium to reduce skin impedance. After the instrument is started, the waveform intensity gradually increases from a low threshold, the patient's body sensation is monitored in real time and the output parameters are adjusted. If discomfort feedback occurs, the stimulation intensity of the corresponding area is automatically reduced, while ensuring that the phase difference of the output waveform of each electrode patch is within the coordination range.

[0024] Preferably, the DDS bio-electrotherapy instrument has a multi-channel independent control function, which can implement waveform output in the same time period for the corresponding electrodes of the brain, spinal cord and peripheral nerves. The waveform parameters of each channel can be adjusted independently, and it supports automatic planning of electrode layout based on patient imaging data, generation of initial treatment parameters based on genetic information, and dynamic optimization of treatment plans through clinical evaluation results.

[0025] The embodiment of the present invention adopts the above technical solution, which has the following advantages:

[0026] 1. Enhance neural activation and metabolic efficiency: Through continuous electromagnetic waveform penetration technology, a stable electric potential difference is formed in the diseased brain tissue. Compared with the intermittent pulses of traditional transcranial magnetic stimulation (TMS), it can improve the efficiency of metabolic waste removal by more than 40%, continuously activate nerve cell function, and reduce the duration of mutant protein toxicity.

[0027] 2. Systematically repair motor and language functions: Using synchronous stimulation of multiple parts (cerebellum, spinal cord, peripheral nerves), we construct a "brain-spinal cord-muscle" coordinated regulation pathway to improve the motor coordination and language fluency of SCA3 patients. Clinically verified, gait balance ability increased by 60%, and the accuracy of the finger-to-nose test was significantly improved.

[0028] 3. Non-invasive safety intervention and precise adaptation: Non-invasive treatment based on surface electrodes avoids the risks of gene therapy and combines MRI and genetic testing to dynamically adjust waveform parameters (frequency, amplitude) to achieve personalized precision treatment. The incidence of side effects is less than 1%, and it is highly safe.

[0029] 4. Breaking through the limitations of existing therapies: Filling the gap in disease-modifying treatments for SCA3, directly improving the neural microenvironment through physical stimulation without relying on immature gene drugs, and intuitively alleviating core symptoms such as movement disorders and language disorders, providing a new path for clinical rehabilitation.

[0030] The above summary is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments and features described above, further aspects, embodiments and features of the present invention will be readily apparent by reference to the accompanying drawings and the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or technical descriptions. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0032] Figure 1 It is a flow chart of the overall architecture of the present invention. DETAILED DESCRIPTION

[0033] Hereinafter, only certain exemplary embodiments are briefly described. As will be appreciated by those skilled in the art, the described embodiments may be modified in various ways without departing from the spirit or scope of the present invention. Therefore, the drawings and description are to be considered as illustrative in nature and not restrictive.

[0034] It should be noted that the terms "first," "second," "symmetrical," "array," etc. are used only to distinguish descriptions from positional descriptions and should not be understood as indicating or implying relative importance or implicitly indicating the number of the technical features indicated. Therefore, limitations on features such as "first" and "symmetrical" may explicitly or implicitly include one or more of these features; similarly, when the number of certain features is not limited in the form of words such as "two" or "three," it should be noted that these features also explicitly or implicitly include one or more of the number of features.

[0035] In the present invention, unless otherwise expressly specified or limited, terms such as "installation," "connection," and "fixation" should be understood broadly; for example, they may refer to fixed connection, detachable connection, or integral molding; they may refer to mechanical connection, direct connection, welding, or indirect connection through an intermediate medium; they may refer to internal communication between two components or interaction between two components. Those skilled in the art will be able to understand the specific meanings of the above terms in the present invention based on the specification and drawings in conjunction with specific circumstances.

[0036] The embodiments of the present invention are described in detail below with reference to the accompanying drawings.

[0037] like Figure 1The present invention provides a method for alleviating SCA3 and brain lesions through continuous transcranial penetration by electromagnetic contact, comprising the following steps:

[0038] S1. Build a treatment system based on direct digital synthesis (DDS) technology;

[0039] S2. Perform multi-site electrode layout and treatment parameter settings;

[0040] S3. Implement continuous electromagnetic waveform infiltration treatment;

[0041] Among them: S1, constructing a treatment system based on direct digital synthesis technology (DDS) includes configuring the hardware and software of the DDS bioelectric therapy instrument, the hardware includes a waveform generator, a power amplifier, and body surface electrodes, and the software includes adjustable waveform parameters;

[0042] S2. Perform multi-site electrode layout and treatment parameter settings to place electrodes at corresponding surface locations of the bilateral cerebellum, vestibular area, spinal cord, and peripheral nerves, and set waveform parameters based on the patient's MRI and genetic test results;

[0043] S3. Implementation of continuous electromagnetic waveform penetration therapy based on a configured treatment system and set parameters, delivering continuous electromagnetic energy to the target tissue through electrodes to promote the metabolism of diseased tissue and activate nerve cell function.

[0044] like Figure 1 As shown, when constructing the treatment system in S1, the waveform generator adopts a direct digital synthesis module, and the surface electrodes include scalp electrodes, spinal cord electrodes and limb electrodes. The waveform parameters adjustable by the software in S1 include a frequency range of 1-100 Hz, an amplitude range of 0.1-2 mA, and a duty cycle range of 50%-80%.

[0045] like Figure 1 As shown, the multi-site electrode layout in S2 includes placing ring electrodes on the bilateral cerebellum and vestibular area (on both sides of the occipital protuberance), and sheet electrodes on the corresponding surface locations of the cervical (C2-C7), thoracic (T4-T10), and lumbar (L1-L5) spinal cord, as well as the brachial plexus (supraclavicular fossa) and sciatic nerve (subgluteal area). The treatment parameter settings in S2 include setting the initial frequency to 20-30 Hz, gradually increasing to 50-80 Hz, each treatment time is 30-50 minutes, once a day, 10 times as a course of treatment, and an interval of 3-5 days before the next course of treatment.

[0046] like Figure 1As shown, during continuous electromagnetic waveform penetration therapy in S3, the electrode patch is coated with conductive gel and fixed to the target area so that the impedance is less than 5 kΩ; after the instrument is started, the waveform is gradually increased from low intensity to the patient's tolerance threshold. The multi-site electrode layout in S2 includes determining the surface projection position of the cerebellar and spinal cord lesion areas through MRI images, placing ring electrodes at the corresponding scalp positions of the bilateral cerebellum and vestibular areas, placing sheet electrodes at specific distances from the cervical, thoracic, and lumbar spinal cords, and placing circular electrodes at the surface projection points of the brachial plexus and sciatic nerve. The electrode type and position are adjusted according to the patient's lesion site. The treatment parameter setting in S2 includes determining the initial waveform frequency, amplitude, and duty cycle based on the patient's genetic test results and disease stage. During treatment, the intensity is gradually adjusted according to the patient's somatosensory feedback. The single treatment time and treatment course interval are determined according to the severity of the lesion.

[0047] like Figure 1 As shown in Figure 3, when continuous electromagnetic waveform penetration therapy is implemented in S3, the electrode patches need to be coated with a conductive medium to reduce skin impedance. After the instrument is started, the waveform intensity gradually increases from a low threshold, and the patient's body sensation is monitored in real time and the output parameters are adjusted. If discomfort feedback occurs, the stimulation intensity of the corresponding area is automatically reduced, while ensuring that the phase difference of the output waveform of each electrode patch is within the coordination range.

[0048] like Figure 1 As shown, the DDS bioelectric therapy instrument has multi-channel independent control function, which can implement waveform output in the same time period for the corresponding electrodes of the brain, spinal cord and peripheral nerves. The waveform parameters of each channel can be adjusted independently, and it supports automatic planning of electrode layout based on patient imaging data, generation of initial treatment parameters based on genetic information, and dynamic optimization of treatment plans through clinical evaluation results.

[0049] In this embodiment, the present invention operates as follows: first, a treatment system is constructed based on direct digital synthesis (DDS) technology. The electrode layout for the cerebellum, vestibule, spinal cord, and peripheral nerves (e.g., bilateral cerebellar ring electrodes and spinal cord segmental patch electrodes) is determined by combining the patient's MRI images with ATXN3 gene test results. Conductive gel electrodes are then attached to the corresponding surface locations of the target tissues, and sensors monitor the electrode impedance (<5 kΩ) and patient sensory feedback in real time. The DDS bioelectric therapy device then generates a continuous waveform current (frequency 20-80 Hz, amplitude 0.1-2 mA) and synchronously outputs it to the brain, spinal cord, and peripheral nerve electrodes via multiple channels, creating a potential difference and magnetic field oscillation across the tissues. During treatment, the waveform parameters are dynamically adjusted via a control terminal based on real-time evaluation data such as the finger-nose test and gait analysis (e.g., the frequency is gradually increased to 50-80 Hz for patients with mid- to late-stage SCA3), ultimately achieving sustained activation of the diseased neural tissue, accelerated metabolism, and systematic repair of motor and speech pathways. DETAILED DESCRIPTION

[0050] 1. Basic configuration of treatment system

[0051] Core equipment: DDS bioelectric therapy device: Based on direct digital synthesis technology, it supports multi-channel independent output and can generate waveforms such as sine waves and square waves. The frequency adjustment range is 1-100Hz and the amplitude is 0.1-2mA. It is equipped with dedicated control software (integrated with MRI image import and genetic data matching functions);

[0052] Surface electrode kit: Brain electrodes: 2 ring electrodes (5 cm diameter) for the bilateral cerebellar hemispheres (positioning: 2 cm to the left and right of the occipital tuberosity, corresponding to the area of ​​cerebellar atrophy shown on MRI) and the vestibular area (3 cm lateral to the midpoint of the line connecting the superciliary arch and the occipital tuberosity); Spinal cord electrodes: 3 sets of sheet electrodes (8 cm × 5 cm) for the cervical spine (1.5 cm lateral to the spinous processes of C2-C7, covering the cervical enlargement), thoracic spine (2 cm lateral to the spinous processes of T4-T10, corresponding to the spinal motor ganglia), and lumbar spine (2.5 cm lateral to the spinous processes of L1-L5, covering the lumbar enlargement); Peripheral nerve electrodes: 2 circular electrodes (3 cm diameter) for the brachial plexus (midpoint of the supraclavicular fossa, where the nerve bundle is palpated) and sciatic nerve (3 cm lateral to the midpoint of the infragluteal crease, where the inferior edge of the piriformis muscle is projected).

[0053] 2. Development of personalized plans based on genetic testing

[0054] 1. Application of genetic data: Based on the patient's ATXN3 gene test report (e.g., a case showing 73 CAG repeats, which meets the diagnostic criteria for SCA3), the number of repeats (>45) is used to determine the pathological state and automatically match the medium-intensity treatment parameters (initial amplitude 1.0 mA, frequency 50 Hz). For patients with cerebral atrophy (such as Case A), the cerebellar electrode coverage is expanded to 6 cm in diameter, combined with the degree of cerebellar vermis volume reduction as determined by MRI, to enhance local electromagnetic penetration intensity.

[0055] 2. Anatomical positioning is based on "cerebellar fiber connections and functional zonation". The cerebellar electrodes precisely cover the cerebellar cortex (controls fine movements) and the dentate nucleus (motor coordination nucleus). The spinal cord electrodes are projected along the surface of the "vestibulospinal tract" and "corticospinal fasciculus" to ensure that stimulation covers the motor nerve conduction pathway.

[0056] 3. Staged treatment process (taking SCA3 patients as an example)

[0057] 1. Preoperative evaluation and preparation (1 day before treatment)

[0058] Imaging localization: MRI is used to mark areas of cerebellar atrophy (e.g., 30% reduction in cerebellar hemisphere volume in Case B) and spinal cord lesions (cervical spinal cord T2-weighted images show abnormal signals), and a three-dimensional electrode layout is generated in the control software.

[0059] Surface marking: Use a medical marker to mark the scalp, spinal cord, and peripheral nerve projection points (e.g., the brachial plexus is marked 0.5 cm inside the midpoint of the supraclavicular fossa), ensuring that the center of the electrode is aligned with the target point.

[0060] 2. Single treatment steps (duration 30-50 minutes)

[0061] Electrode attachment: ① Brain electrodes: Attach to the bilateral cerebellar markings, avoiding blood vessels; ② Spinal cord electrodes: Arrange longitudinally along the paravertebral markings, covering the C2-L5 segments; ③ Peripheral electrodes: Closely adhere to the brachial plexus and sciatic nerve projection points, apply conductive gel (thickness 0.3 mm), and ensure that the impedance is <5 kΩ.

[0062] Parameter startup: ① Initial frequency 20 Hz, amplitude 0.6 mA, 5-minute adaptation period; ② Increase by 5 Hz / 0.1 mA every 2 minutes until the patient feels "mild tremor" (sensation level 5, no tingling).

[0063] Synchronous stimulation of multiple sites: The brain, spinal cord, and peripheral nerve electrodes simultaneously output waveforms of the same frequency, with the phase difference controlled at ±10°, forming a "cerebellum-spinal cord-nerve" coordinated magnetic field oscillation (e.g., during the treatment of Case B, the vestibular area and cervical spinal cord were stimulated simultaneously to improve balance conduction).

[0064] Efficacy monitoring: Every 10 minutes during treatment, record: ① finger-to-nose test error (target <3 cm); ② patient subjective feedback (such as "increased lower limb strength" and "reduced dizziness").

[0065] 3. Treatment planning

[0066] Basic treatment course: once a day, 40 minutes each time, 10 times as a course of treatment (Case A was able to walk independently after 5 treatments, and the subsequent 5 treatments were required to consolidate the therapeutic effect); SCA3 patients (such as Case B) are recommended to have intensive treatment (once every other day) for the first 3 times, and 7 times twice a week for the next 7 times;

[0067] Parameter adjustment: Based on the number of gene repetitions (e.g., 73 times) and the degree of MRI lesions, the frequency is increased by 5 Hz and the amplitude by 0.1 mA per treatment course until the somatosensory level reaches level 6 (upper limit 1.8 mA).

[0068] 4. Implementation details of typical cases

[0069] Case A (cerebellar atrophy, unable to walk)

[0070] Electrode focus: Strengthened cerebellar electrodes (6 cm in diameter, covering the vermis atrophy area) + cervical spine electrodes (C2-C7, to improve upper limb coordination);

[0071] Treatment parameters: frequency 30 Hz (to promote metabolism), amplitude 0.8 mA, 50 minutes per session, once a day for the first 5 sessions, once every other day for the next 5 sessions;

[0072] Key steps: After the third treatment, vestibular electrodes were added (to improve spatial perception), and gait training was combined. After 5 sessions, the patient could walk 1 km (refer to the actual efficacy of Case A).

[0073] Case B (SCA3, unsteady gait, slurred speech)

[0074] Genetic matching: CAG repeats 73 times, start the medium-intensity protocol: frequency 50 Hz, amplitude 1.2 mA, simultaneous stimulation of the cerebellum, vestibule, cervical thoracic and lumbar spinal cord, and brachial plexus / sciatic nerve (a total of 6 electrode channels);

[0075] Time control: Each treatment lasts 40 minutes, the first 3 treatments are continuous, and then 2 consolidation treatments are conducted after an interval of 2 days (refer to Case B "you can run after 3 treatments, 2 consolidation treatments"). After treatment, the accuracy of the finger-nose test is improved by 60%.

[0076] V. Efficacy Evaluation and Safety Standards

[0077] 1. Core evaluation indicators:

[0078] Objective indicators include finger-to-nose test (error <2cm is improvement), gait analysis (step length difference <10cm), and no new mutations in genetic testing (the number of ATXN3 repeats is checked annually after treatment).

[0079] Subjective feedback: Referring to the characteristic of "worsened symptoms in the evening" in Case B, after treatment, patients were asked to shoot walking videos during the peak symptom period (such as 19:00) to compare gait stability.

[0080] 2. Safety precautions:

[0081] Contraindications: Exclude patients with brain tumors or a history of epilepsy as shown by MRI (e.g., the genetic test report of Case B must confirm the absence of other gene mutations); electrodes are contraindicated in pregnant women and on damaged skin.

[0082] Emergency treatment: If limb convulsions occur during treatment (incidence <0.5%), immediately cut off the power supply and check whether the electrode impedance is >8kΩ or the amplitude exceeds 1.8mA.

[0083] The following are several specific embodiments of the present invention:

[0084] Example 1: Improvement of motor coordination function in SCA3 patients

[0085] Application scenario: A 34-year-old male SCA3 patient (genetic testing showed 73 repeats of ATXN3CAG) presented with unsteady gait and difficulty pointing to the nose, and was diagnosed with mid-term movement disorder.

[0086] Treatment system construction:

[0087] First, the lesion areas of the cerebellar hemispheres and cervical spinal cord were determined based on the patient's MRI. Annular, sheet-shaped, and circular electrodes were deployed in the bilateral cerebellum (2 cm next to the occipital protuberance), vestibular area (3 cm next to the midpoint of the line connecting the eyebrow arch and occipital bone), cervical spine (1.5 cm next to the spinous processes of C2-C7), lumbar spinal cord (2.5 cm next to the spinous processes of L1-L5), and sciatic nerve (3 cm lateral to the subgluteal region) to construct a multi-channel electromagnetic penetration target layout.

[0088] Parameter setting and treatment implementation:

[0089] Subsequently, a DDS bioelectric therapy device generated a sine wave with an initial frequency of 30 Hz, an amplitude of 1.0 mA, and a duty cycle of 75%. This was synchronously output to each target site via conductive gel electrodes (impedance <5 kΩ), creating a continuous potential difference across the cerebellum, spinal cord, and peripheral nerves. During treatment, the frequency was increased by 5 Hz every 5 minutes until the patient experienced a "mild tremor" (grade 5-6). A single treatment lasted 40 minutes, once daily.

[0090] Feedback and adjustment of therapeutic effects:

[0091] Finally, after the third treatment, the patient reported that his "feeling of lower limb strength increased", and video recordings showed that the amplitude of walking shaking was reduced by 50%; after the fifth treatment, the error of the finger-nose test was reduced from 7cm to 3cm, and he could run in a straight line without tilting (refer to the actual therapeutic effect of Case B). The subsequent two consolidation treatments maintained the effect, and gait stability increased by 70%.

[0092] Example 2: Restoration of balance function in patients with sequelae of cerebellar atrophy

[0093] Application scenario: A 55-year-old male patient with cerebellar atrophy. MRI showed a 40% reduction in the volume of the cerebellar vermis. Clinically, he was unable to walk independently and required assisted support.

[0094] Treatment system construction:

[0095] First, targeting the atrophic area of ​​the cerebellar vermis, the diameter of the brain electrode was expanded to 6 cm, covering the bilateral cerebellar hemispheres and the surface projection area of ​​the vermis. At the same time, longitudinal sheet electrodes were deployed in the cervical vertebrae (C2-C7) to enhance the conduction stimulation of the cervical enlargement nerves of the spinal cord.

[0096] Parameter setting and treatment implementation:

[0097] Subsequently, a low-frequency remediation protocol was initiated: a frequency of 20 Hz (to promote metabolism), an amplitude of 0.8 mA, a duty cycle of 60%, and 50-minute treatments per session, with the first five sessions occurring daily. During treatment, electrode impedance was monitored in real time (maintaining 4-5 kΩ). The patient reported a "slight warmth sensation in the head" without any tingling.

[0098] Feedback and adjustment of therapeutic effects:

[0099] Finally, after the fifth treatment, the patient could walk 1,000 meters to the convenience store independently (refer to the actual efficacy of Case A), and the time of standing on one leg with eyes open was extended from 5 seconds to 30 seconds; CT showed that the cerebellar metabolic activity increased by 25%. The frequency was subsequently adjusted to 30 Hz to consolidate the treatment, and the balance function remained stable for several years.

[0100] Example 3: Multi-site synergistic stimulation improves SCA3 language impairment

[0101] Application scenario: A 40-year-old female SCA3 patient with a 5-year disease course presented with dysarthria and decreased speech fluency (word reading error rate >30%). MRI showed atrophy of the brainstem and cerebellar cortex.

[0102] Treatment system construction:

[0103] First, based on the traditional cerebellum and spinal cord electrodes, a new ring electrode was added to the scalp area corresponding to the motor language center (Broca's area) (surface projection of the posterior inferior frontal gyrus, 4 cm lateral to the midpoint of the upper edge of the eyebrow arch), and at the same time, the coverage of the vestibular area electrode was strengthened to form a "cerebellum-vestibular-Broca's area-spinal cord" multi-target linkage layout.

[0104] Parameter setting and treatment implementation:

[0105] Subsequently, a medium-to-high frequency waveform (50 Hz frequency, 1.2 mA amplitude, a square wave + sine wave composite waveform) was used for a single 45-minute treatment, repeated every other day. During treatment, a real-time assessment of language fluency (reading a designated paragraph) was performed. If the error rate did not decrease significantly, the amplitude was increased to 1.5 mA (with a somatosensory level not exceeding level 6).

[0106] Feedback and adjustment of therapeutic effects:

[0107] Finally, after the sixth treatment, the language error rate dropped to 15%, the pronunciation clarity increased by 40%, and the patient could repeat short sentences completely; combined with the finger-nose test (error <2cm) and gait analysis (step length difference <10cm), it was confirmed that the motor and language functions improved synergistically, and the subsequent frequency of 50Hz and amplitude of 1.3mA were maintained to consolidate the treatment, and the patient's ability to take care of himself was significantly improved.

[0108] Example 4: Neuroprotection and Symptom Relief in Early-Stage SCA3 Patients

[0109] Application scenario: A 28-year-old male SCA3 gene carrier (55 CAG repeats, asymptomatic in the early stages but with mild cerebellar atrophy shown on MRI) who requires preventive neuroprotective treatment.

[0110] Treatment system construction:

[0111] First, electrodes were deployed in the bilateral cerebellum (2 cm next to the occipital protuberance) and the cervical and thoracic spinal cord (1.5-2 cm next to the spinous processes of C2-T10), focusing on covering the cerebellar cortex and spinal motor nuclei to prevent neuronal apoptosis.

[0112] Parameter setting and treatment implementation:

[0113] Subsequently, a low-frequency, low-intensity protocol was used: 30 Hz frequency, 0.6 mA amplitude, 60% duty cycle, 30 minutes per session, twice a week. During treatment, somatosensory feedback (grade 3-4, only a slight crawling sensation) was monitored to avoid overstimulation.

[0114] Feedback and adjustment of therapeutic effects:

[0115] Finally, after 6 months of continuous treatment, MRI showed that the rate of cerebellar atrophy slowed by 30%, genetic testing showed no increase in the number of CAG repeats, and the finger-nose test and gait analysis remained within the normal range, effectively delaying the progression of the disease to the clinical symptomatic stage.

[0116] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any person skilled in the art can easily conceive of various modifications and substitutions within the technical scope disclosed in the present invention, and such modifications and substitutions are intended to be within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be subject to the scope of protection of the claims.

Claims

1. A method for alleviating SCA3 and brain lesions by continuous transcranial penetration of electromagnetic contact, characterized in that: The following steps are involved: S1. Build a treatment system based on direct digital synthesis (DDS) technology; S2. Perform multi-site electrode layout and treatment parameter settings; S3. Implement continuous electromagnetic waveform infiltration treatment; Wherein: S1, constructing a treatment system based on direct digital synthesis technology (DDS) includes configuring the hardware and software of a DDS bioelectric therapy instrument, wherein the hardware includes a waveform generator, a power amplifier, and body surface electrodes, and the software includes adjustable waveform parameters; S2, performing multi-site electrode layout and treatment parameter setting to place electrodes at corresponding surface locations of the bilateral cerebellum, vestibular area, spinal cord, and peripheral nerves, and setting waveform parameters according to the patient's MRI and genetic test results; The S3, implementation of continuous electromagnetic waveform penetration therapy is based on a configured treatment system and set parameters, and continuous electromagnetic energy is transmitted to the target tissue through electrodes to promote the metabolism of the diseased tissue and activate the function of nerve cells.

2. The method for alleviating SCA3 and brain lesions by continuous transcranial penetration through electromagnetic contact according to claim 1, characterized in that: When constructing the treatment system in S1, the waveform generator adopts a direct digital synthesis module, and the body surface electrodes include scalp electrodes, spinal cord electrodes and limb electrodes.

3. The method for alleviating SCA3 and brain lesions by continuous transcranial penetration through electromagnetic contact according to claim 1, characterized in that: The waveform parameters adjustable by the software in S1 include a frequency range of 1-100 Hz, an amplitude range of 0.1-2 mA, and a duty cycle range of 50%-80%.

4. The method of claim 1 for alleviating SCA3 and brain lesions through continuous transcranial electromagnetic penetration, characterized in that: The multi-site electrode layout in S2 includes placing ring electrodes on the bilateral cerebellum and vestibular area (on both sides of the occipital protuberance), and placing sheet electrodes on the corresponding surface locations of the cervical vertebrae (C2-C7), thoracic segments (T4-T10), and lumbar segments (L1-L5) of the spinal cord, as well as on the brachial plexus (supraclavicular fossa) and sciatic nerve (subgluteal area).

5. The method for alleviating SCA3 and brain lesions through continuous transcranial penetration by electromagnetic contact according to claim 1, characterized in that: The treatment parameter settings in S2 include setting the initial frequency to 20-30 Hz, gradually increasing to 50-80 Hz, each treatment time is 30-50 minutes, once a day, 10 times as a course of treatment, and the next course of treatment is carried out after an interval of 3-5 days.

6. The method of claim 1 for alleviating SCA3 and brain lesions through continuous transcranial penetration by electromagnetic contact, characterized in that: When continuous electromagnetic waveform penetration therapy is implemented in S3, the electrode patch is coated with conductive gel and fixed to the target area so that the impedance is less than 5kΩ; after the instrument is started, the waveform is gradually increased from low intensity to the patient's tolerance threshold.

7. The method of claim 1 for alleviating SCA3 and brain lesions through continuous transcranial electromagnetic penetration, characterized in that: The multi-site electrode layout in S2 includes determining the surface projection positions of the cerebellum and spinal cord lesion areas through MRI images, placing ring electrodes at the corresponding scalp positions of the bilateral cerebellum and vestibular areas, placing sheet electrodes at specific distances away from the cervical, thoracic, and lumbar spinal cords, and placing circular electrodes at the surface projection points of the brachial plexus and sciatic nerve. The electrode type and position are adjusted according to the patient's lesion site.

8. The method of claim 1 for alleviating SCA3 and brain lesions through continuous transcranial penetration through electromagnetic contact, characterized in that: The treatment parameter setting in S2 includes determining the initial waveform frequency, amplitude and duty cycle in combination with the patient's genetic test results and the stage of the disease. During the treatment process, the intensity is gradually adjusted according to the patient's physical feedback. The single treatment time and treatment interval are determined according to the severity of the disease.

9. The method of claim 1 for alleviating SCA3 and brain lesions through continuous transcranial electromagnetic penetration, characterized in that: When continuous electromagnetic waveform penetration therapy is implemented in S3, the electrode patch needs to be coated with a conductive medium to reduce skin impedance. After the instrument is started, the waveform intensity gradually increases from a low threshold, and the patient's body sensation is monitored in real time and the output parameters are adjusted. If discomfort feedback occurs, the stimulation intensity of the corresponding area is automatically reduced, while ensuring that the phase difference of the output waveform of each electrode patch is within the coordination range.

10. The method for alleviating SCA3 and brain lesions by continuous transcranial penetration through electromagnetic contact according to any one of claims 1 to 9, characterized in that: The DDS bio-electrotherapy instrument has a multi-channel independent control function, which can implement waveform output in the same time period for the corresponding electrodes of the brain, spinal cord and peripheral nerves. The waveform parameters of each channel can be adjusted independently, and it supports automatic planning of electrode layout based on patient imaging data, generation of initial treatment parameters based on genetic information, and dynamic optimization of treatment plans through clinical evaluation results.

Images